You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 4,720,489


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,720,489
Title: Hair growth modification with ornithine decarboxylase inhibitors
Abstract:The rate and character of human hair growth including androgen-stimulated beard hair growth in intact, sexually mature males is altered by the topical application out of a dermatologically acceptable carrier of a material capable of inhibiting the action of the enzyme ornithine decarboxylase. In a preferred practice of the invention, compositions containing such materials along with anti-androgen material are employed.
Inventor(s): Shander; Douglas (Gaithersburg, MD)
Assignee:
Application Number:06/661,019
Patent Claims: 1. The process of reducing the rate and altering the character of human hair growth which comprises the step of applying to the skin a composition containing an ornithine decarboxylase inhibitor.

2. The process as described in claim 1 in which said ornithine decarboxylase inhibitor is selected from the group including 2-(difluoromethyl)-2,5-diaminopentanoic acid; alpha-ethynyl ornithine; 6-heptyne-2,5-diamine; and 2-methyl-6-heptyne diamine.

3. The process as described in claim 2 resulting in the application of from about 1 to about 2000 micrograms of said ornithine decarboxylase inhibitor per square centimeter of skin.

4. The process as described in claim 2 resulting in the application of from about 50 to about 500 micrograms of said ornithine decarboxylase inhibitor per square centimeter of skin.

5. The process as described in claim 1 and in which said composition contains in addition an anti-androgen material selected from the group consisting of 5-alpha-reductase inhibitors and cytoplasmic androgen receptor-binding agents.

6. The process as described in claim 5 in which said anti-androgen is selected from the group consisting of progesterone; (5.alpha., 20-R)-4-diazo-21-hydroxy-20-methyl pregnan-3-one; (4R)-5-10-seco-19-Norpregna4,5-diene-3,10,20 trione; 4-androstene-3-one-17-carboxylic acid, and its methyl ester; 17-.beta.-N,N-diethylcarbamoyl-9-methyl4-aza-5.alpha.-androstane-3-one; 11-.alpha.-OH-progesterone; 17-.alpha.-OH-progesterone; and 20-.alpha.-OH-progesterone; cyproterone acetate; chlormadinone acetate; 17-alpha-propyltestosterone; 17-alpha-allyltestosterone; .alpha.-.alpha.-.alpha.-trifluoro-2-methyl-4'-nitro-m-propionotoluidide; 6.alpha.-bromo-17.beta.-hydroxy-17.alpha.-methyl-4-oxa-5.alpha.-androstane -3-one; 17.beta.-acetoxy-4.alpha.,5cyclo-A-homo-B-nor-5.alpha.-androst-1-ene-3one; and spironolactone.

7. The process as described in claim 6 in which about 1 to about 500 micrograms of said anti-androgen is applied per square centimeter of skin.

8. A topical composition for reducing the rate and altering the character of human hair growth comprising from about 0.01 to about 20% by weight of an ornithine decarboxylase inhibitor in combination with from about 0.01 to 10% by weight of an anti-androgen selected from the group consisting of 5-alpha-reductase inhibitors and cytoplasmic androgen receptor-binding agents.

9. A composition as described in claim 8 in which said ornithine decarboxylase inhibitor is selected from the group including 2-(difluoromethyl)-2,5-diaminopentanoic acid; alpha-ethynyl ornithine; 6-heptyne-2,5-diamine; and 2-methyl-6-heptyne diamine and said anti-androgen is selected from the group including progesterone; (5.alpha., 20-R)-4-diazo-21-hydroxy-20-methyl pregnan-3-one; (4R)-5-10-seco-19-Norpregna4,5-diene-3,10,20 trione; 4-androstene-3-one-17-carboxylic acid, and its methyl ester; 17-.beta.-N,N-diethylcarbamoyl-9-methyl4-aza-5.alpha.-androstane-3-one; 11-.alpha.-OH-progesterone; 17-.alpha.-OH-progesterone; and 20-.alpha.-OH-progesterone; cyproterone acetate; chlormadinone acetate; 17-alpha-propyltestosterone; 17-alpha-allyltestosterone; .alpha.-.alpha.-.alpha.-trifluoro-2-methyl-4'-nitro-m-propionotoluidide; 6.alpha.-bromo-17.beta.-hydroxy-17.alpha.-methyl-4-oxa-5.alpha.-androstane -3-one; 17.beta.-acetoxy-4.alpha.,5cyclo-A-homo-B-nor-5.alpha.-androst-1-ene-3one; and spironolactone.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.